Selskabets formål er forskning og udvikling af farmaceutiske produkter for selskaber i Ferring koncernen.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.7 mia. | 76.9 mio. | 554.5 mio. | 266.2 mio. | 487 | |
CVR: 16313440
Previous names: A/S PSE 38 NR. 1587, FERRING NORDIC PHARMACEUTICALS A/S
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Pierre Yves Berclaz left the board
Ingbritt Tolstrup Birk joined as director
Lene Melchiorsen left as director
Tamara Vukmirovic joined as director
Jesper Thomsen joined the board
Jesper Thomsen left the board
Jesper Thomsen joined as director
Anette Hedegaard Østergaard left as director
Klaus Grønbæk Jakobsen left as director
Ferring Pharmaceuticals A/S demonstrates a solid financial trajectory, with revenue increasing from 1,005 million DKK in 2021 to 1,690 million DKK in 2024, reflecting a strong growth trend. Profitability has also improved, rising from 40 million DKK in 2021 to 76.9 million DKK in 2024, indicating effective cost management and operational efficiency. The company's equity has significantly strengthened, climbing from 69.6 million DKK in 2021 to 266.2 million DKK in 2024, which enhances its financial stability. However, the lack of available employee data and a CDS score may raise concerns regarding transparency and risk assessment within the competitive landscape of scientific research and development. Overall, Ferring Pharmaceuticals is well-positioned for continued growth within its industry.
AI-generated summary
Companies in the same industry and area
companydata.dk